Clinical Trial Update: SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of SAR3419 as a single agent in relapsed-refractory diffuse large B-cell lymphoma (DLBCL) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• SAR3419

Snippet

Sponsor: Sanofi | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED